Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jonathan Wade Goldman, Jean-Charles Soria, Heather A. Wakelee, D. Ross Camidge, Shirish M. Gadgeel, Helena Alexandra Yu, Karen L. Reckamp, Vassiliki Papadimitrakopoulou, Maurice Perol, Sai-Hong Ignatius Ou, Shannon L. Matheny, Darrin Despain, Jeffrey D. Isaacson, Sergey Yurasov, Lindsey Rolfe, Lecia V. Sequist
Institutions: UCLA Medical Center, Institut Gustave Roussy, Stanford Medicine, The Barbara Ann Karmanos Cancer Institute, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Hospices Civils de Lyon, University of California, Irvine, Clovis Oncology (United States), Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891328671